EGFR anticorps (AA 956-985)

N° du produit ABIN391933

Cet anticorps Lapin Polyclonal détecte spécifiquement EGFR dans WB. Il présente une réactivité envers Humain.

Aperçu rapide pour EGFR anticorps (AA 956-985) (ABIN391933)

Antigène: EGFR (Epidermal Growth Factor Receptor (EGFR))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp EGFR est non-conjugé

Application: Western Blotting (WB)

Clone: RB10971

Détail du produit anti-EGFR anticorps

Épitope: AA 956-985

Homologie: M

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogène: This EGFR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 956-985 amino acids from human EGFR.

Isotype: Ig Fraction

Information d'application

Indications d'application: WB: 1:1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Date de péremption: 6 months

Détails sur EGFR

Antigène: EGFR (Epidermal Growth Factor Receptor (EGFR))

Autre désignation: EGFR

Sujet: EGFR is a transmembrane glycoprotein that is a member of a family of protein tyrosine kinases crucial in maintaining a normal balance in cell growth and development. A prototype member of the type 1 receptor tyrosine kinases, EGFR is encoded by the cellular oncogene cerbB1. EGFR has an extracellular ligand binding domain, a single transmembrane region, and cytoplasmic domain which is composed of a tyrosine kinase domain and a carboxy terminal domain. The carboxy terminal domain contains at least four tyrosine autophosphorylation sites. Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. EGFR overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

Poids moléculaire: 134277

ID gène: 1956

NCBI Accession: NP_005219, NP_958439, NP_958440, NP_958441

UniProt: P00533

Pathways: Signalisation NF-kappaB, Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteins